Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

NCT Number	NCT07224347
Lead Sponsor	Anne Murray Collaborators: National Health and Medical Research Council, Australia, Bayer, Monash University, Berman Center for Outcomes and Clinical Research, National Institute on Aging (NIA), National Cancer Institute (NCI)
Conditions	Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Enrollment	19,114 participants
Start Date	2019-07-15
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-04